- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05758389
Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors
January 19, 2024 updated by: Jing Yan, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
A Prospective Single-center, Single-arm Clinical Study of the PD-1 Inhibitor Tislelizumab Combined With APF Sequential Surgery or Radical Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Head and Neck Tumors
The goal of this clinical trial is to test in describe participant population. The main questions it aims to answer are:
- evaluate the efficacy and safety of tislelizumab combined with APF sequential surgery or radical concurrent chemoradiotherapy in the treatment of locally advanced head and neck tumors.
- the exploration of efficacy-related immune microenvironment genes Participants will receive tislelizumab combined with APF sequential surgery or radical concurrent chemoradiotherapy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
29
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jing Yan
- Phone Number: +86 15805182426
- Email: firefreebird@163.com
Study Contact Backup
- Name: Kongcheng Wang
- Phone Number: +86 13814165197
- Email: wangxxbz@126.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Recruiting
- Department of Oncology, Drum Tower Hospital, Nanjing University School of Medicine
-
Contact:
- Jing Yan
- Phone Number: +86 15805182426
- Email: firefreebird@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18-75 years old;
- Histological or cytology-confirmed head and neck tumors (including oral, oropharynx, hypopharynx, larynx) squamous cell carcinoma, etc.;
- Have at least one radiographically measurable lesion (RECIST 1.1 criteria);
- The clinical stage is III-IVb (P16-) or II-III (P16+);
- There are tumor samples that can detect gene expression;
- ECOG score 0-1 points;
- Have not received radiotherapy and chemotherapy or other anti-tumor drugs before;
- The following hematological indicators need to be met: (1) Neutrophil count≥ 1.5×109/L; (2) Hemoglobin≥ 10g/dL; (3) Platelet count ≥ 100×109/L
- The following biochemical indicators need to be met: (1) Total bilirubin ≤1.5× upper limit of normal value (ULN); (2) AST and ALT < 1.5 ×ULN; (3) Creatinine clearance ≥ 60ml/min; (4) Alkaline phosphatase ≤ 5 times ULN; (5) Activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤1.5xULN (for anticoagulation at a stable dose such as low molecular weight heparin or warfar.) LIN and INR can be screened within the expected therapeutic range of anticoagulants)
- Subjects of childbearing age need to take appropriate protective measures (contraceptive measures) before enrollment and in trials administration or other methods of birth control);
- Have signed informed consent;
- Ability to follow study protocols and follow-up procedures.
Exclusion Criteria:
- Received anti-tumor treatment in the past 6 months, including radiotherapy and chemotherapy, surgery, immunotherapy Wait;
- Previously or concurrently suffering from other malignant tumors (except for malignant tumors that have been cured and survived for more than 5 years without cancer, such as skin basal cell carcinoma, cervical carcinoma in situ, superficial bladder cancer, and thyroid papillary carcinoma, etc.);
- There is distant metastasis;
- Active autoimmune diseases, history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); but excludes autoimmune-mediated hypothyroidism on stable doses of thyroid replacement hormone; type 1 diabetes on stable doses of insulin; vitiligo or resolved childhood asthma/allergies, Patients who do not require any intervention after adulthood;
- Known history of primary immunodeficiency (including positive HIV test, or suffering from other acquired or congenital immunodeficiency diseases, or history of organ transplantation and allogeneic bone marrow transplantation);
- Severe infection (CTC AE>2 grade) occurred within 4 weeks before the first use of the study drug, such as severe pneumonia requiring hospitalization, bacteremia, infection complications, etc.; baseline chest imaging examination showed active lung Inflammation, symptoms and signs of infection within 2 weeks before the first use of the study drug or the need for oral or intravenous antibiotic treatment (excluding prophylactic use of antibiotics);
- The subject has severe liver and kidney dysfunction, HIV infection, HCV infection, uncontrolled clinical symptoms or diseases of the heart, such as: heart failure above NYHA grade II or echocardiography showing left ventricular ejection fraction (LVEF) < 50%; unstable angina; myocardial infarction within 1 year; patients with clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention (including QTc interval ≥ 470 ms); uncontrolled diabetes, uncontrolled Patients with high blood pressure, hypertensive crisis or hypertensive encephalopathy or other diseases considered by the researchers to be ineligible;
- Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) DNA exceeding 500 IU/ml, or patients with active hepatitis C virus (HCV) should be excluded; inactive hepatitis B surface Antigen carriers, treated and stable hepatitis B patients (HBV DNA<500IU/ml), and cured hepatitis C patients can be enrolled;
- Have a history of interstitial lung disease (excluding radiation pneumonitis that has not been treated with hormones) and non-infectious pneumonia;
- Active tuberculosis infection was found through medical history or CT examination, or patients with a history of active tuberculosis infection within 1 year before enrollment, or patients with a history of active tuberculosis infection more than 1 year ago but without formal treatment;
- Patients who have received any of the following treatments (1) Subjects who need to be given corticosteroids (> 10 mg prednisone equivalent dose per day) or other immunosuppressants for systemic treatment within 2 weeks before the first use of the study drug, except for local inflammation and prevention of allergies and nausea, Cases of use of corticosteroids for vomiting. In the absence of active autoimmune disease, corticosteroid replacement with inhaled or topical steroids and curative doses of prednisone >10 mg/day is permitted; (2) Have been vaccinated against tumors; those who have been vaccinated or have been vaccinated with live vaccines within 4 weeks before the first administration of the study drug; (3) Received major surgery or severe trauma within 4 weeks before the first use of the study drug; (4) Enrolled in another clinical study at the same time;
- Pregnant and lactating women. Women of childbearing age must take a pregnancy test within 7 days before enrollment Negative;
- Substance abuse, clinical or psychological or social factors that hinder informed consent or research conduct influences;
- Those who may be allergic to the study drug;
- Those who cannot perform radiotherapy and chemotherapy due to social or geographical factors;
- Significant weight loss within 6 weeks before enrollment (weight loss ≥ 10%);
- Any uncertain factors affecting the safety or compliance of the subjects;
- Contraindications to hormone use.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: immunotherapy combined with chemotherapy
|
evaluate the efficacy and safety of immunotherapy combined with chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of pathological examination
Time Frame: Change from Baseline pathologic examination at the end of Cycle 3 (each cycle is 21 days)
|
Changes in pathologic examination before treatment and after 3-cycle induction therapy were evaluated to derive the number and proportion of patients with pathological complete remission
|
Change from Baseline pathologic examination at the end of Cycle 3 (each cycle is 21 days)
|
Change of tumor size
Time Frame: Change from baseline tumor size at the end of Cycle 3 (each cycle is 21 days)
|
imaging (MRI or CT) assessment according to RECIST v1.1 was performed and documented during follow-up as required
|
Change from baseline tumor size at the end of Cycle 3 (each cycle is 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Security assessment
Time Frame: At the end of Cycle 3 (each cycle is 21 days)
|
according to the NCI-CTCAE 4.0 adverse reaction evaluation criteria
|
At the end of Cycle 3 (each cycle is 21 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 7, 2023
Primary Completion (Estimated)
June 7, 2024
Study Completion (Estimated)
June 7, 2025
Study Registration Dates
First Submitted
January 17, 2023
First Submitted That Met QC Criteria
February 24, 2023
First Posted (Actual)
March 7, 2023
Study Record Updates
Last Update Posted (Actual)
January 23, 2024
Last Update Submitted That Met QC Criteria
January 19, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-666-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Tumors
-
IntraGel TherapeuticsNot yet recruiting
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
Royal Marsden NHS Foundation TrustRoyal Brompton and Harefield NHS Foundation TrustUnknown
-
University College, LondonWithdrawnHead and Neck Cancer
-
Institut du Cancer de Montpellier - Val d'AurelleCompleted
-
University Hospital, GhentCompleted
-
University Hospital HeidelbergCompletedHead and Neck CancerGermany
-
Royal Marsden NHS Foundation TrustRoyal Brompton and Harefield NHS Foundation TrustCompleted
-
Juergen DebusRecruiting
-
Nanospectra Biosciences, Inc.CompletedHead and Neck CancerUnited States
Clinical Trials on Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityDongguan People's HospitalRecruitingHead and Neck Squamous Cell Carcinoma | Neoadjuvant TreatmentChina
-
Washington University School of MedicineCelgene CorporationCompletedSquamous Cell Carcinoma of the Head and NeckUnited States
-
Sun Yat-sen UniversityUnknown
-
Peking UniversityNot yet recruitingThoracic Esophageal Squamous Cell CarcinomaChina
-
Sun Yat-sen UniversityRecruiting
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaboratorsNot yet recruitingCervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant ChemoimmunotherapyChina
-
Peking UniversityTerminated
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaboratorsNot yet recruitingCervical Cancer | Fertility Preservation | Radical Hysterectomy | Neoadjuvant ChemoimmunotherapyChina
-
West China HospitalRecruitingHead and Neck Squamous Cell CarcinomaChina
-
The First Affiliated Hospital with Nanjing Medical...RecruitingEsophageal Squamous Cell Carcinoma | Locally Advanced CarcinomaChina